Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shared details on Tuesday about its pivotal Phase 3 program of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME) and began first patient dosing, anticipated in the first quarter of 2026.

DME is the leading cause of vision loss in type 1 and type 2 diabetes patients. Damaged blood vessels leak fluid into the macula, the central portion of the retina responsible for sharp vision needed for routine tasks such as driving or reading.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.